Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SGP · NASDAQ · Surgical & Medical Instruments & Apparatus
Spyglass Pharma (SGP) · oqro.io/stocks/SGP · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$32.88−0.44 (−1.32%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
No open-market purchase by an insider of Spyglass Pharma is on record in SEC filings since 2006.
No open-market sale by an insider of Spyglass Pharma (SGP) was filed with the SEC in the last 90 days.
No trade in Spyglass Pharma (SGP) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+24.5% (+$6.48) from Feb 6, 2026 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $26.40 on Feb 6, 2026 to $32.88 on Nov 13, 2026 (+24.5%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in Irvine, Ca.
Last 12 months
Not enough history
Market value
$1.1B
Short interest: 1.16M shares sold short (3.5% of shares outstanding), −5.2% vs the previous count, 12.1 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
−$16.8M
This quarter −$16.8M, a year earlier −$6.38M
Net debt
—
Debt —, cash $223M, at Jun 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Fund moves
3 tracked managers disclosed the same change for Q1 2026. Among this manager's largest new positions for Q1 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
0 certified in FY2026 Q3, vs 0 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Against the S&P 500 over the year
Since Feb 6, 2026, SGP is up 24.5% and the index fund is up 9.2%: 15 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SGP moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
2 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in cataract. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
